Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 18/20 | 0.62 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16452856 | 0.94 | AVPR1B (0.62) | AVPR1BAVPR1A | |
| SCHEMBL16424324 | 0.89 | AVPR1B (0.79) | AVPR1BAVPR1A | |
| SCHEMBL16424429 | 0.89 | AVPR1B (0.50) | AVPR1BMAPT | |
| SCHEMBL16424158 | 0.87 | AVPR1B (0.80) | AVPR1BAVPR1A | |
| SCHEMBL16424351 | 0.86 | AVPR1B (0.49) | AVPR1BMAPT | |
| SCHEMBL16423903 | 0.85 | AVPR1B (0.52) | AVPR1B | |
| SCHEMBL16423968 | 0.85 | AVPR1B (0.60) | AVPR1B | |
| SCHEMBL16424196 | 0.85 | AVPR1B (0.64) | AVPR1BAVPR1A | |
| SCHEMBL16442142 | 0.84 | AVPR1B (0.46) | AVPR1BMAPT | |
| SCHEMBL16442145 | 0.84 | AVPR1B (0.55) | AVPR1BAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045551-A1 | FUSED AZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045551-A1 | FUSED AZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2832722-A1 | FUSED AZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-2832722-A1 | FUSED AZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045551-A1 | FUSED AZOLE DERIVATIVE | AVPR1B, AVPR1A, GRIN2B | AVPR1B 1/4885AVPR1A 2/4885MAPT 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.